AstraZeneca and Sanguina are working together to develop a customized version of the latter's AnemoCheck Mobile app that would allow for bloodless blood testing of patients with anemia by analyzing photos of their nailbeds to measure hemoglobin levels.
Pfizer will be able to deliver 10% more COVID-19 vaccine doses to the US by the end of May to meet the company's target of delivering 300 million doses two weeks ahead of schedule, according to a tweet from CEO Albert Bourla.
Abzena is building a $213 million state-of-the-art biologics production facility in Sanford, N.C. The contract drug manufacturing organization has facilities in England, California and Pennsylvania and is making an antibody therapy for COVID-19 developed by Immunome.
The acquisition of Ology Bioservices adds 200,000 square feet to Resilience's manufacturing space, along with $1.8 billion in US government contracts. Ology has a multi-product facility in Alachua, Fla., with space for four 2,000-liter single-use bioreactor runs, and a smaller facility for ex vivo gene therapies is being built in Alameda, Calif.
Catalent has completed an $85 million expansion of its drug substance manufacturing facility in Madison, Wis., that added two mammalian cell culture suites. The company hired about 150 employees and plans to hire another 150 in the next year, says product manager Stacey Treichler.
IBM says a hacking campaign uncovered last year that targeted the COVID-19 vaccine cold chain affected more than 40 companies in 14 countries, "and the campaign remains a deliberate and calculated threat." Hackers claiming to represent Qingdao Haier Biomedical sent emails with malicious attachments labeled as requests for quotes for a solar-powered vaccine refrigerator and other equipment, which IBM researchers say suggests the actors had "exceptional knowledge of the cold chain."
Shortages of bioreactor bags and filters means Novavax will not hit its target of 150 million COVID-19 vaccine doses a month until sometime in the third quarter, Novavax Communications Director Amy Speak said. "Single-use bags are facing critical shortages and delays," said Mark Womack, chief business officer at AGC Biologics, which makes materials used in Novavax's vaccine.
Swiss Interior Ministry officials will work with other government agencies on strategies to "strengthen the development and production of COVID-19 medicines, including vaccines and treatment, in Switzerland," the government said. Switzerland has already changed regulations to facilitate domestic production.
Logistics and shipping companies including Cryoport, Tribe Transportation and Cold Chain Technologies are expanding their capability to handle complex biologic drugs, gene therapies and vaccines, which require stable temperature control throughout the transportation chain. Cold Chain Technologies CEO Ranjeet Banerjee expects the proportion of drugs that will need temperature-controlled handling to rise to one-third within the next two years as more biologic drugs and gene therapies hit the market.
Moderna on Tuesday announced that, based on results from a six-month follow-up of participants in a Phase 3 trial, its COVID-19 vaccine continues to provide strong protection against the virus six months after the second dose was given, with efficacy against all types of COVID-19 cases at more than 90% and more than 95% against severe COVID-19. The company is also working on versions of the vaccine that target the variant B.1.351.
- Page 1